Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease

Trial Profile

A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PQ 912 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms SAPHIR; SAPHIR 1
  • Sponsors Probiodrug; Vivoryon Therapeutics
  • Most Recent Events

    • 16 Oct 2018 According to a Probiodrug media release, data from this trial has been published in the journal Alzheimer's Research & Therapy.
    • 31 Aug 2018 Biomarkers information updated
    • 30 Aug 2018 According to a Probiodrug media release, data from this trial was presented at the 255th National Meeting & Exposition of the American Chemical Society (ACS) (Mar 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top